Astria Therapeutics, Inc.

Astria Therapeutics, Inc.

ATXS·NASDAQ

$12.58

+0.0000%
HealthcareBiotechnology

Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage for the treatment of hereditary angioedema. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is based in Boston, Massachusetts.

At a Glance

Live Snapshot
Market Cap$718.13M
EPS-1.6800
P/E Ratio-7.49
Earnings Date03/10/2026

atxs

Net Cash Provided by Financing Activities

Last Annual Value

157.20M

3-Year CAGR

15%

5-Year CAGR

44%

10-Year CAGR

42%

Astria Therapeutics, Inc.

Astria Therapeutics, Inc. Competitors Analysis of Net Cash Provided by Financing Activities

ATXS · NASDAQ
CompanyNet Cash Provided by Financing Activities
CAGR 3Y
CAGR 5Y
CAGR 10Y
157.20M
21.2%8.6%32.9% 
300.77M
-13.4%4.7%12.0%
ERAS logo
Erasca, Inc.
NASDAQ:ERAS
1.10M
-5.4%-69.8%N/A
203.06M
68.0%17.7%N/A
189.59M
39.9%N/AN/A
252.40M
-6.8%-7.5%N/A
ARVN logo
Arvinas, Inc.
NASDAQ:ARVN
-91.40M
N/AN/AN/A
1.22M
-80.5%-66.7%N/A
17.77M
N/A-59.0%N/A
12.27M
-47.3%48.3%-5.1%
Astria Therapeutics, Inc.

Astria Therapeutics, Inc. Fair Value Envelope

ATXS · NASDAQ

Our analysis suggests that ATXS has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $12.58, this represents a potential HIDDEN relative to our calculated worth for Astria Therapeutics, Inc..

Intrinsic Value
Current Price: $12.58